CanariaBio has entered into a distribution and licence agreement with Hikma MENA FZE, part of Hikma Pharmaceuticals, for oregovomab to treat advanced ovarian cancer.
Hikma MENA FZE will distribute oregovomab in the Middle East and North Africa (MENA) region.
CanariaBio CEO Michael Na stated: “We are thrilled to partner with Hikma, a company with a strong presence in the MENA region and a proven track record of successful collaborations.”
Oregovomab, a murine monoclonal antibody, targets the tumour-associated antigen CA125 that stimulates a host cytotoxic immune response against tumour cells that express the CA 125 biomarker.
A randomised Phase II study of oregovomab together with first-line chemotherapy showed a significant improvement in progression-free survival of 41.8 months against 12.2 months with standard chemotherapy.
It also demonstrated improvements in overall survival with a hazard ratio of 0.35.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Oregovomab along with carboplatin and paclitaxel is also being investigated in the Phase III FLORA-5 trial in patients with advanced ovarian cancer.
It received orphan drug designations from the European Medicines Agency and the US Food and Drug Administration.
Hikma executive vice-chairman and MENA president Mazen Darwazah stated: “We have been actively expanding our oncology portfolio through research and development and in-licensing, in order to address unmet medical needs in different types of cancer and bring renewed hope to cancer patients in the MENA region.
“We believe Oregovomab can potentially improve the treatment outcomes for patients with advanced primary ovarian cancer.”
In addition to the MENA region, Hikma has a presence in North America and Europe and makes its medicines accessible to those in need.
Source link
#CanariaBio #partners #Hikma #MENA #FZE #oregovomab
